United States

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

10:05am EST
Change (% chg)

$0.02 (+0.25%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Get access to over 18 million research reports from over 1,700 sources.

For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.

Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.

Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:

  • ownership
  • filings
  • deals
  • private equity
  • third-party document and information retrieval
  • estimates
  • fundamentals
  • economics
  • events
  • news
  • and much, much more…

Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.

Name Age Since Current Position

Armen Shanafelt

59 2014 Independent Chairman of the Board

Anthony Quinn

55 2017 Interim Chief Executive Officer, Director

George Georgiou

56 Co-Founder, Director

Charles York

39 2015 Chief Financial Officer, Vice President

Henry Hebel

44 2015 Vice President - Product Development